Topics

Sarepta tries softer approach to resolve FDA setback

06:30 EST 8 Nov 2019 | BioPharmaDive

Departing from the combative tack taken by Sarepta with Exondys 51, CEO Doug Ingram appears to be reading from a new playbook in handling Vyondys 53's rejection.

Original Article: Sarepta tries softer approach to resolve FDA setback

NEXT ARTICLE

More From BioPortfolio on "Sarepta tries softer approach to resolve FDA setback"

Quick Search